培哚普利治疗原发性高血压及对血管炎性因子和内皮功能的作用  

作　　者：许雨良[1] 

机构地区：[1]杭州市中医院心内科,310000

出　　处：《浙江临床医学》2013年第6期794-796,共3页Zhejiang Clinical Medical Journal

摘　　要：目的观察培哚普利治疗原发性高血压的临床疗效及对血管炎性因子、内皮功能的影响。方法高血压患者100例，随机分为观察组和对照组，各50例，观察组给予培哚普利治疗，对照组给予坎地沙坦酯治疗，比较二者临床疗效，以及治疗前后血浆血浆中高敏C反应蛋白（hs-CRP）、血浆纤维蛋白原（FIB-C）和内皮素1（ET-1）、一氧化氮（NO）的含量变化。结果观察组显效37例、有效12例、无效1例，总有效率98.00%，对照组显效35例、有效13例、无效2例，总有效率96.00%，差异无统计学意义。两组患者治疗前血浆hs-CRP及FIB-C水平差异均无统计学意义，治疗12周后，两组患者血浆hs-CRP及FIB-C水平均下降（P〈0.05），观察组下降幅度更大（P〈0.01）；两组患者治疗前血浆ET-1及NO水平，差异均无统计学意义，治疗12周后，两组患者血浆ET-1水平下降、NO水平上升（P〈0.05），观察组变化幅度更大（P〈0.01）。两组患者治疗期间均未出现严重的药物不良反应。结论培哚普利可以有效控制原发性高血压，抑制患者血管炎症反应，改善血管内皮功能，促进患者康复。Objective To investigate the clinical efficacy of perindopril treatment on primary hypertension , vascular inflammatory factors and endothelial function. Methods 100 patients compliant random number was divided into observation group and the control group, 50 patients in the observation group were given perindopril treatment, the control group was given candesartan cilexetil, their clinical efficacy, and plasma plasma high-sensitivity C-reactive protein （ hs-CRP ） were compared before and after treatment, plasma fibrinogen （ FIB-C ） and endothelin-1 （ ET-1 ） , nitric oxide （ NO ） content. Results After 12 weeks of treatment, the observation group, 37 cases had markedly effect in 12 cases and 1 case was ineffective, the total effective rate was 98.00%; the control group, 35 cases markedly effective in 13 cases and 2 cases were ineffective, the total effective rate was 96.00%, the difference was not statistically significant （P〉0.05） .Plasma hs-CRP and FIB-C levels in the two groups of patients before treatment comparison, the difference was not statistically significant （ i~〉0.05 ） ; After 12 weeks of treatment, the two groups of patients with plasma hs-CRP and FIB-C levels decreased （P〈0.05） , bui the observation group were decreased substantially greater （ P〈0.01 ） .The plasma ET-1 and NO levels in the two groups of patients before treatment were compared, the difference was not statistically significant （ P〉0.05 ） ; After 12 weeks of treatment, the two groups of patients with plasma ET-1 levels decreased, NO levels increased （P〈0.05） , However, the observation group had more variations （P〈O.O1） . During treatment, the two groups of patients had no serious adverse drug reactions. Conclusion Perindopril can effectively control primary hypertension, inhibition of vascular inflammation in patients, improve endothelial function, and promote the rehabilitation of patients, therefore is worthy of clinical application.

关 键 词：原发性高血压 培哚普利 血管炎性因子 血管内皮功能 

分 类 号：R541.4[医药卫生—心血管疾病]